Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors. [electronic resource]
Producer: 20160907Description: 601-12 p. digitalISSN:- 0890-9091
- Adenocarcinoma -- drug therapy
- Antineoplastic Agents -- therapeutic use
- Biomarkers, Tumor -- genetics
- Disease Progression
- Drug Resistance, Neoplasm -- drug effects
- ErbB Receptors -- genetics
- Humans
- Lung Neoplasms -- drug therapy
- Mutation
- Neoplasm Staging
- Protein Kinase Inhibitors -- therapeutic use
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Quality of Life
- Randomized Controlled Trials as Topic
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.